hypnotics – reducing & stopping medicine optimisation the slides have been adapted from the...
TRANSCRIPT
HYPNOTICS – Reducing & Stopping
Medicine Optimisation
The slides have been adapted from the NPC slide set available athttp://www.npc.nhs.uk/qipp/qipp_elearning/hypnotics_elearning.php
Practices to review and, where appropriate, revise prescribing of hypnotics to ensure that it is in line with national guidance
Options for local implementationNPC. Key therapeutic topics – Medicines management options for local implementation. Second update July 2011
Key questions
What are the recommendations on hypnotics?
What are the risks and benefits of hypnotics?
Do Z-drugs have advantages over benzodiazepine hypnotics?
How are we doing with prescribing?
How can people who want to withdraw from hypnotics be supported?
Problems associated with the long-term use of benzodiazepines
Adverse effects Drowsiness and falls Impairment in judgement and dexterity Increased risk of experiencing a road traffic accident Forgetfulness, confusion, irritability, aggression and paradoxical
disinhibition
Complications related to long-term use Depression Reduction in coping skills Tolerance and dependence
Dependence (one or more of following)
Patients gradually ‘need’ benzodiazepines to carry out normal day-to-day activities
Patients continue to take benzodiazepines although the original indication for the prescription is no longer relevant
Patients have difficulty stopping treatment or reducing dosage due to withdrawal symptoms
Short acting benzodiazepines may cause patients to develop anxiety symptoms between doses
Patients contact their doctor regularly to obtain repeat prescriptions Patients become anxious if the next prescription is not readily available Patients may increase the dosage stated in the original prescription Despite benzodiazepine therapy, patients may present with recurring
anxiety symptoms, panic, agoraphobia, insomnia, depression and an increase in physical symptoms of anxiety
Insomnia
A common disorder characterised by unsatisfactory sleep(sleep onset, sleep maintenance, early waking)
Predominantly a long-term disorder Before treatment rule out any potential causes of insomnia
External factors (light, noise, room temperature) Change in sleep environment (e.g. hotel) Physiological disturbance (e.g. shift work, daytime napping) Jet lag Acute illness Psychological factors (e.g. anxiety, depression, stressful life events) Substance misuse and drug withdrawal Stimulant use (e.g. caffeine, nicotine, OTC or prescribed medicines)
Perform sleep assessment (& anxiety rating)
Non-drug approachesClinical Knowledge Summaries. Last revised July 2009
CBT (Cognitive Behaviour Therapy)
Good sleep hygiene
Regular exercise
Relaxation
MHRA advice on benzodiazepines in insomnia(CSM. Curr Problems Pharmacovigilance. January 1988, No. 21)
Should be used only if insomnia is severe, disabling or subjecting the patient to extreme distress
Use lowest dose, for maximum of four weeks
Use intermittently, if possible, for insomnia
Taper off gradually
NICE guidance: newer hypnotics (Z-drugs)NICE technology appraisal 77, April 2004
No compelling evidence of a clinically useful difference between the Z-drugs and shorter-acting benzodiazepines from the point of view of their effectiveness, adverse effects, or potential for dependence or abuse
The drug with the lowest purchase cost should be prescribed
Switching from one of these hypnotics to another should only occur if a patient experiences adverse effects considered to be directly related to a specific agent. These are the only circumstances in which the drugs with the higher acquisition costs are recommended
Patients who have not responded to one of these hypnotic drugs should not be prescribed any of the others.
Hypnotics for insomniaSPCs for zopiclone, zolpidem, zaleplon; www.medicines.org.uk Zopiclone, Zolpidem
Short–term treatment of insomnia…in situations where the insomnia is debilitating or is causing severe distress for the patient
Long–term continuous use is not recommended
The duration of treatment should be limited to 4 weeks, including any tapering off
Zaleplon
A single course of treatment should not continue for longer than 2 weeks
What would happen to 13 people like you who take sleeping tablets for more than a weekGlass J, et al. BMJ 2005;331:1169
The hypnotic makes no difference to what happens to these 12 people. Their sleep improves, or doesn’t improve, just as if they had taken
placebo.
This person finds his/her sleep improves, who would not have done had he or she taken the
placebo
These 2 people have an adverse event, who would not have done had they taken the
placebo.
The hypnotic makes no difference to what happens to these 11 people.
They have adverse events, or don’t have adverse events, just as if they
had taken placebo.
Increased risk of road traffic accidents Gustavsen I, et al. Sleep Med 2008;9:818–22 www.npc.nhs.uk/rapidreview/?p=249
Cohort study of Norwegian drivers, aged 18 to 69 years
People prescribed zopiclone or zolpidem had double the risk of road traffic accidents (RTAs), compared with people not prescribed hypnotics
Standardised incidence ratio (SIR) of hypnotic use in previous 7 days, compared with no use:
Zopiclone or zolpidem — SIR 2.3 (95%CI 2.0 to 2.7)
Nitrazepam — SIR 2.7 (95%CI 1.8 to 3.9)
Flunitrazepam — SIR 4.0 (95%CI 2.4 to 6.4)
Absolute rates (per exposed 1000 person-years) of RTAs were:
about 5 to 9 accidents in groups treated with hypnotics
about 2 accidents in the group not exposed to hypnotics
Hip fractures and benzodiazepinesWagner AK, et al. Arch Intern Med 2004;164:1567–72
Incident relative risk of hip fracture with benzodiazepine (BZD) vs. no BZD use based on US claims data (194,071 person years of data, 1988-90): Any BZD exposure: 1.24 (95%CI 1.06 to 1.44) Long half-life BZD only: 1.13 (0.82 to 1.55) NS Short half-life high potency: 1.27 (1.01 to 1.59) Short half-life low potency: 1.22 (0.89 to 1.67) NS >1 BZD type: 1.53 (0.92 to 2.53) NS New BZD <16 days: 2.05 (1.28 to 3.28) New BZD 16–30 days: 1.88 (1.15 to 3.07) Continued BZD: 1.18 (1.03 to 1.35)
NS – No significant difference
Authors conclude: incidence of hip fracture appears to be associated with benzodiazepine use
Note: Different doses were not considered
Hypnotic QIPP data Q4 2012 -13(Cumbria, Northumbria, Tyne & Wear)
QIPP Prescribing ProfileJanuary to March 2013
Select Indicator:
Hypnotics ADQ/STAR PU, Cumbria,Northumb,Tyne & Wear Area TeamPeriod: January to March 2013
0.72 0.87 0.77 0.79 0.56 1.01 1.04 0.940.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
Ga
tesh
ea
d C
CG
Ne
wca
stle
No
rth
An
d E
ast
CC
G
Ne
wca
stle
We
stC
CG
No
rth
um
be
rla
nd
CC
G
So
uth
Tyn
esi
de
CC
G
Su
nd
erl
an
dC
CG
Cu
mb
ria
CC
G
No
rth
Tyn
esi
de
CC
G
Lower the Better
Hypnotics ADQ/STAR PU
Hypnotic QIPP data Q4 2012 -13(Cumbria Practices)
Hypnotics ADQ/STAR PU, Practice: A82077-Liverpool House Surgery Period : January to March 2013
QIPP Comparator Description
QIPP Prescribing ProfileJanuary to March 2013
Total number of average daily quantities (ADQs) for benzodiazepines (indicated for use as hypnotics) & “Z” drugs per Star-PU*.
Hypnotics ADQ/STAR PU, Practice: A82077-Liverpool House Surgery Period : January to March 2013
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
Wra
ysd
ale
Trin
ity H
se
The
Fam
ily
Warw
ick R
d
Fuseh
ill
Westc
roft H
se
Lo
wth
er
Ed
en
Ha
wkshe
ad
Asp
atr
ia
Gro
sve
no
r H
se
(W
ard
)
The
Cro
ft
Wig
ton
Orc
hard
Hse
Bru
nsw
ick H
se
Mansio
n H
se
Ca
theri
ne
St
Ne
lson S
t
Mary
port
Nu
twoo
d
Du
ke
St
Sp
en
ce
r S
t
Bri
dg
ega
te
Da
lto
n
Gro
sve
no
r H
se
(W
igm
ore
)
Lu
nesd
ale
Ca
stleh
ead
Ca
ldb
eck
Dis
ting
ton
Bu
rnett
Ed
ga
r
The
La
ke
s
Als
ton
So
lwa
y
Que
en S
t
Ha
ve
rthw
aite
Sill
oth
Bra
mp
ton
Du
ddo
n V
alle
y
Ulv
ers
ton (
Murr
ay)
Tem
ple
Sow
erb
y
Atk
inson
Pa
rk V
iew
De
rwent
Hse
Co
urt
Th
orn
The
Jam
es C
ochra
ne
Gle
nrid
din
g
Ha
rtin
gto
n S
t
Sta
tion H
se
Bir
be
ck
Ris
edale
St
Pa
uls
No
rwod
Lo
ngto
wn
Wate
rloo
Hse
Fellv
iew
Ca
pta
in F
rench
Sta
nw
ix
Se
db
erg
h
Ca
rtm
el
Jam
es S
t
Da
lsto
n
Liv
erp
ool H
se
Ulv
ers
ton (
Gra
ham
)
Ap
ple
by
Up
per
Ede
n
Arn
sid
e
Be
nth
am
Sh
ap
Ba
nk S
t
Ca
stleg
ate
Askam
Win
derm
ere
Ab
be
y R
d
Am
ble
sid
e
Pe
nin
sula
Kir
kosw
ald
St.
Mary
's
Se
ascale
Be
echw
ood
Sto
ne
leig
h
Gro
sve
no
r H
se
(F
rost)
Other Localities Selected Practice Selected Locality Upper Quartile Target England Average
Lower the Better
How can people who want to withdraw from hypnotics be supported? Older people are not always being given appropriate safety
warnings about taking these drugsIliffe S, et al. Aging Ment Health 2004;8:242–8
It is difficult to withdraw from hypnotic drugs
A letter from the GP can be effective in helping some to stopCormack MA, et al. Br J Gen Pract 1994;44:5–8
CBT can be helpful Morgan K, et al. HTA 2004:8(8)
See CKS guidance for further information
Published criteria for clinical audit are availableNICE TA77, April 2004; Shaw E, Baker R. J Clin Governance 2001;9:45–50
Key messages
Non-drug treatments should be considered and used routinely in all patients
1988 CSM advice re benzodiazepines still stands and is also applicable to Z-drugs
NICE guidance confirms that Z-drugs offer little or no advantage over benzodiazepines
However, overall prescribing of hypnotics is not decreasing Hypnotics should be used at lowest dose for max 4 weeks for
severe insomnia only Consider auditing hypnotic use and changing practice Resources exist for managing withdrawal
Suggested Practice Actions(1)
All prescribers must agree to be engaged and involved with the project Circulate to all prescribers the Welsh information pack, which containers
sample letters, sleep guides, reduction schedules etc.- email to all prescribers- electronic copy on surgery information folder - hard copy to be kept by medicine manager- easily accessible for reference- decide which parts are useful – print off?
Identify patients who receive hypnotics on repeat and acute- Medicine Mangers to search for last 12 months
Establish the demographics of patients- who to look at first?
Younger patients? (may be diverting supplies. If don’t stop now, may have many years of benzo use ahead of them)
Elderly patients? (at greater risks of falls, maybe on older medicines e.g. nitrazepam) Patients on high doses?
Middle aged group?
Suggested Practice Actions(2) Patient selection
- For each prescriber, a list of patients to be produced, based on which GP has seen the patient last or is most familiar with a patient. GPs can do ‘swaps’, if they wish! Need to make sure the numbers are divided fairly equally.- GP to go through the list, and eliminate anyone who has a genuine reason for being on the drug, or feel would be too difficult a challenge to start with.- GPs to identify one or two patients to call in for a medication review to discuss the issue, and start reducing the dose. (method to be decided)
Each month, one or two more patients selected. This is a gradual process - the numbers will build up slowly but steadily, depending on the workload created by withdrawing patients. Some patients may be deemed too difficult to stop completely but even a reduction in dose or a switch to a shorter acting drug is preferable to doing nothing.
The reduction method should be discussed and tailored to each individual patients needs converting to equivalent diazepam dose, and reducing slowly reducing the dose of the drug gradually reducing the number of tablets supplied for a set time period i.e. having
drug free nights e.g. 25 tablets lasting 28 days etc. The patient needs to see the same GP during the reduction schedule, especially if
the patient is requesting the dose to be increased back up.
Suggested Practice Actions(3)
New Patients prescribed hypnotics- only prescribe if absolutely clinically essential - seven days supply only, as an acute script (Good Practice)- label as ‘ one at night, if required’- zopiclone = Lothian Joint Formulary 2nd choice (1st choice = no treatment)- give patient ‘Good sleep guide/Good relaxation guide’- no repeat prescriptions for new patients
At prescribing meetings within the practice, suggest analysing prescribing of hypnotics within the last 3 months to determine if any patients have been commenced and continued on hypnotics, and the reasons why.
Transferred patients- Any new patients registering with the practice from another surgery on hypnotics will have their medication discussed and reviewed at their initial consultation.
The message that the patient needs to reduce, and eventually stop, their use of these drugs should be re-enforced at every opportunity.
Involvement of the drug and alcohol service should be considered.
Support Material
Cumbria GP Practice guide
Welsh Education Pack
Presentation
Hypnotic Academic Detailing Aid
The Good Sleep Guide
The Good Relaxation Guide
Patient letters
Reduction Protocols
Community Pharmacy support